Commentary

Video

Neoadjuvant Nivolumab Plus Ipilimumab in dMMR Colon Cancer: The NICHE-2 Trial

Author(s):

Sakti Chakrabarti, MD,Mohammed Najeeb Al Hallak, MD, MS

Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, on data for neoadjuvant nivolumab plus ipilimumab in dMMR colon cancer.

Related Videos
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, discuss ongoing research in gastrointestinal cancers.
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, discuss research building upon approved combinations in unresectable hepatocellular carcinoma.
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, on trastuzumab deruxtecan–based regimens in advanced HER2-positive GI cancers.
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, on final overall survival data from the KEYNOTE-811 trial.
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, on tremelimumab/durvalumab vs atezolizumab/bevacizumab in unresectable HCC.
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, on 5-year data for tremelimumab plus durvalumab in unresectable HCC.
Kimmie Ng, MD, MPH
Cathy Eng, MD, FACP, FASCO
Kimmie Ng, MD, MPH
Kimmie Ng, MD, MPH
Related Content
John L. Marshall, MD, of Georgetown Lombardi Comprehensive Cancer Center
October 28th 2024

ctDNA Generates Momentum in Adjuvant Stage II/III Colon Cancer Setting

Delve into Recent NCCN Guideline Updates for Hepatobiliary and CRC Management: With Alan P. Venook, MD
October 24th 2024

Delve into Recent NCCN Guideline Updates for Hepatobiliary and CRC Management: With Alan P. Venook, MD

John H. Strickler, MD
October 21st 2024

Telisotuzumab Adizutecan Represents a Novel c-Met–Targeting ADC in MET-Amplified CRC

Oncology Unplugged
August 21st 2024

Park and Kasi Expand on Perioperative Immunotherapy Updates in CRC

Kristen K. Ciombor, MD, MSCI
October 11th 2024

Treatment Personalization Is Poised to Define New Era of mCRC Therapy

Todd Aguilera, MD, PhD, assistant professor, radiation oncology, UT Southwestern Medical Center
October 10th 2024

Sotigalimab May Be a Safe and Feasible Addition to the Rectal Cancer Chemoradiotherapy Paradigm